<table>
<thead>
<tr>
<th>Title</th>
<th>Exploratory clinical trial of combination wound therapy with a gelatin sheet and platelet-rich plasma in patients with chronic skin ulcers: Study protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Morimoto, Naoki; Kakudo, Natsuko; Matsui, Makoto; Ogura, Tsunetaka; Hara, Tomoya; Suzuki, Kenji; Yamamoto, Masaya; Tabata, Yasuhiko; Kusumoto, Kenji</td>
</tr>
<tr>
<td>Citation</td>
<td>BMJ Open (2015), 5(5)</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2015-05-11</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/2433/216066">http://hdl.handle.net/2433/216066</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</td>
</tr>
<tr>
<td>Type</td>
<td>Journal Article</td>
</tr>
<tr>
<td>Textversion</td>
<td>publisher</td>
</tr>
</tbody>
</table>

Kyoto University
BMJ Open

Exploratory clinical trial of combination wound therapy with a gelatin sheet and platelet-rich plasma in patients with chronic skin ulcers: study protocol

Naoki Morimoto,1 Natsuko Kakudo,1 Makoto Matsui,2 Tsunetaka Ogura,1 Tomoya Hara,1 Kenji Suzuki,1 Masaya Yamamoto,2 Yasuhiko Tabata,2 Kenji Kusumoto1


INTRODUCTION

Chronic skin ulcers caused by diabetes mellitus, venous insufficiency, pressure sores, collagen disease, trauma or radiation are intractable and costly problems in healthcare.1–3 In particular, diabetic foot ulcers and venous leg ulcers are frequent and costly complications of the underlying diseases. The prevalence of diabetic foot ulcers ranges from 4% to 10% among patients with diabetes, and the lifetime incidence is reported to be as high as 25%.2–3 It has been reported that venous leg ulcers recur in 72% of cases, and the recurrence rate after skin grafting is 48% within 1 year.4 With the development of tissue engineering, bioengineered skin substitutes and genetically derived growth factors have progressed greatly in recent years with respect to the treatment of chronic skin ulcers.5–7 However, new treatment options for chronic skin ulcers are needed.

Platelet-rich plasma (PRP) is blood plasma enriched with platelets. Autologous PRP is a source of autologous growth factors, such as platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF).8 9 PRP has been used clinically in a variety of treatments for bone defects, tendon injuries, cartilage injuries, cosmetic surgeries and chronic ulcers.10 Regarding the efficacy of PRP in the treatment of chronic wounds, PRP has, in
many reports, been described as improving the rate of healing compared with standard care.11 12 On the other hand, in other studies, no major differences have been found in the healing outcomes of leg ulcers between PRP treatment groups and control groups.11 12

A drug delivery system (DDS) is a type of technology for enhancing the biological activity of growth factors with a very short in vivo half-life after application. Biodegradable hydrogels of gelatin with an isoelectric point (IEP) of 5.0 have been designed and developed for the sustained release of positively charged growth factors, such as basic fibroblast growth factor (bFGF), PDGF-BB and TGF-β1,13–15 The efficacy of a sustained release system for epidermal growth factor was also recently reported.16 PDGF-BB and TGF-β are major growth factors involved in PRP for improving the wound healing process, and enhanced angiogenesis by gelatin microspheres impregnated with PRP has been reported.13 Additionally, gelatin hydrogel sheets have been used to achieve the sustained release of growth factors and can be applied on wounds directly as a wound dressing.17 The wound healing effect of PRP covered with this sheet is expected to be enhanced by the sustained release of growth factors from the gelatin sheet as a result of its biodegradation after application.

In this report, we designed an exploratory clinical study to investigate the safety and efficacy of PRP application covered with our gelatin sheet compared with PRP covered with a hydrocolloid dressing, in the treatment of chronic skin ulcers. In addition, we estimated the contents of PDGF-BB, TGF-β1 and VEGF in PRP, and compared these values and the degree of wound healing associated with the gelatin sheet.

MATERIALS AND ANALYSIS
Primary objective
The objective of this study is to evaluate the safety and efficacy of the administration of PRP in the treatment of chronic skin ulcers that are not expected to heal using conventional treatments.

The safety and efficacy of PRP covered with a gelatin sheet versus a hydrocolloid dressing will also be evaluated.

Methods and design
Open-label, non-randomised, controlled clinical trial.

Design
This study is a prospective cohort study using historical data as a control. A group treated with PRP application covered with a gelatin sheet and a group treated with PRP application covered with a hydrocolloid dressing have been set. Patients will be randomised to the gelatin sheet subgroup or the hydrocolloid dressing subgroup, and a randomisation-based comparison between these groups is expected to achieve significant improvements in accuracy with a lack of bias. This comparison will provide useful information for designing and conducting future trials.

Setting and participants
This study is being conducted at Kansai Medical University Hirakata Hospital and Kansai Medical University Takii Hospital. Patients with chronic skin ulcers are being referred by physicians and identified through a number of wound care clinics in Osaka Prefecture and surrounding prefectures.

Inclusion criteria
1. Patients 20 years of age or older with informed consent.
2. The presence of the following chronic skin ulcers:
   - Not healing for at least 1 month with conventional treatments;
   - Not expected to respond to conventional treatments;
   - Expected to be closed with autologous skin grafting or suturing after PRP treatment;
   - An ulcer area between 3 and 30 cm² (that can be applied with autologous PRP).
3. Written informed consent.

Exclusion criteria
1. Patients showing unstable haemodynamics due to ischaemic heart disease or impaired blood coagulation, as in clotting disorders.
2. Patients taking anticoagulants or antithrombotics judged by the investigator or subinvestigator to be inappropriate as participants since the drugs may affect the clotting system.
3. Any of the following systemic diseases:
   - Uncontrolled diabetes mellitus (defined as a glycated haemoglobin level of ≥10% according to the latest laboratory data obtained within 28 days before registration);
   - Requiring the continued use of oral corticosteroid therapy (>20 mg/day prednisolone equivalent);
   - A history of malignant tumours with a disease-free interval of 3 years or less.
4. Patients who are or plan to be pregnant.
5. Other patients judged by the investigator or sub-investigator to be inappropriate as participants of this study.

Analysis of subgroups
In this study, patients will be randomised to either the gelatin sheet subgroup or hydrocolloid dressing subgroup at a ratio of 1:1 without stratification. Randomisation will be performed by assigning random numbers from random number tables to the treatment conditions.

Interventions
Preparation of PRP
PRP is prepared using the Magellan Autologous Platelet Separator System (Medtronic Inc, Minneapolis, Minnesota,
USA) and its basic disposable kit. PRP is prepared by sampling blood using 60 mL syringes of the basic disposable kit filled with an anticoagulant, and separating and concentrating platelets to threefold or more compared with that observed in the peripheral blood using the Magellan Autologous Platelet Separator System. The obtained PRP is activated as described in our previous study. Briefly, a 1:1 (v/v) mixture of 0.5 M CaCl₂ (Otsuka Pharmaceutical Factory, Inc, Tokushima, Japan) and autologous thrombin is prepared in advance as an activator. A 10:1 (v/v) mixture of PRP and the activator is incubated for 5 min at room temperature. Platelets of prepared PRP are counted, and the concentrations of growth factors (TGF-β1, PDGF-BB and VEGF) in activated PRP are also quantified. If platelets cannot be separated and concentrated threefold or more compared with that in the peripheral blood, the study will be discontinued.

Preparation of the gelatin sheet
Acidic gelatin with an IEP of 5.0 (Nitta Gelatin, Osaka, Japan) is to be used in this study. Gelatin hydrogel sheets of 12×3 cm in size are prepared at the Department of Biomaterial, Field of Tissue Engineering, University of California. The gelatin sheets are cut into pieces 1 cm in size. To cross-link gelatin, an aqueous glutaraldehyde (GA, Wako Pure Chemical Industries, Osaka, Japan) solution (25 wt%) is prepared in advance as an activator. A 10:1 (v/v) mixture of 0.5 M CaCl₂ (Otsuka Pharmaceutical Factory, Inc, Tokushima, Japan) and autologous thrombin is prepared in advance as an activator. A 10:1 (v/v) mixture of PRP and the activator is incubated for 5 min at room temperature. Platelets of prepared PRP are counted, and the concentrations of growth factors (TGF-β1, PDGF-BB and VEGF) in activated PRP are also quantified. If platelets cannot be separated and concentrated threefold or more compared with that in the peripheral blood, the study will be discontinued.

Application of activated PRP and dressing changes
After debridement of the chronic skin ulcers, activated PRP is applied to the lesions. Following the administration of PRP, the wound is dressed with a gelatin hydrogel sheet or conventional hydrocolloid dressing (DuoActive; Convatec, Japan, Tokyo, Japan). The wound is occluded with the above dressing material for 5 days from the beginning of the administration of PRP and treated thereafter by applying ointment, such as Azunol ointment (Nippon Shinyaku Co Ltd, Kyoto, Japan) or wound dressings, until 6 weeks after the administration of PRP.

Secondary endpoints
- Percentage of wound reduction: Before and after the application of PRP, the wound is photographed once a week at dressing change, and the wound area is measured serially.
- Degree of improvement in the blood flow: The skin perfusion pressure or ankle brachial index is measured at dressing changes before and 1 and 4 weeks after the application of PRP.
- Correlations between the ‘time to wound closure’ and the platelet count or growth factor levels in the PRP area.
**Blinding**

In this study, a data monitoring committee was not organised, although the wound closure will be independently measured under blinding by three specialists. The patients will be unblinded, and unblinded investigators will apply PRP and the change dressings.

**Sample size**

This study is a prospective cohort study using historical data as controls, with a total of 30 patients for registration, a feasible size for a pilot study.

**Study schedule**

The schedule of the study assessments and evaluations is shown in table 1. The study period will be from the day of PRP application to 6 weeks after PRP application. Data for evaluating the efficacy and safety of this study will be collected at enrolment, baseline, day 5 and weeks 1, 2, 3, 4, 5 and 6 after application or the day of wound closure.

**Statistical analysis**

The statistical analysis will be performed on the following variables:

- Time to wound closure;
- Percentage of wound reduction;
- Improvement in the blood flow;
- Correlations of the ‘time to wound closure’ with the platelet count and/or growth factor levels in the PRP area;
- Adverse events related to the application of PRP.

The efficacy will be evaluated according to the time from PRP application to wound closure. The survival curves in an existing control group based on historical data and the PRP-treated group until wound closure will be evaluated according to the Kaplan-Meier method, and a stratified analysis will be performed using the log-rank test. A stratified analysis of the number and percentage of patients who show wound closure will be performed using Fisher’s exact test (95% CI).

In addition, the optimal dose of PRP for wound healing will be estimated from the platelet count and growth factor concentrations in the PRP area.

The incidences of adverse events, and adverse events that can be causally related to PRP application, will be evaluated based on the event and severity. An interim analyses and auditing will not be planned; however, the investigators will monitor adverse events and other unintended effects of the trial interventions.

**ETHICS**

This study is being conducted in compliance with the ICH-GCP and in agreement with the latest revision of the Declaration of Helsinki, Pharmaceutical Affairs Law, and all applicable Japanese laws and regulations, as well as any local laws and regulations, and all applicable guidelines.
Participant consent
Informed consent will be obtained from all potential study participants using the Institutional Review Board-approved informed consent form. The clinical investigator informs the potential study participant of all pertinent aspects of the study, and the participant must sufficiently understand the content of the information form before providing written consent. The consent form must be dated and signed by both the investigator and participant. The participants are also informed that their medical care will not be affected if they do not choose to participate in this study. The consent forms will be retained at Kansai Medical University Hirakata Hospital and Kansai Medical University Taki Hospital, and the information form and a copy of the consent form will be handed to the participant. Whenever the investigator obtains information that may affect the participant’s willingness to continue participation in the study, the investigator or subinvestigator will immediately inform the participant and record this observation and subsequently reconfirm the participant’s willingness to continue participation in the study.

DISSEMINATION
The findings of this trial will be disseminated through peer-reviewed journals, and national and international scientific meetings as well as to the patients.

DISCUSSION
This study was designed to address the safety and efficacy of PRP treatment for chronic skin ulcers using a gelatin hydrogel sheet that can sustain the levels of growth factors in the PRP material. This study will be the first controlled trial to evaluate the efficacy of PRP covered with a hydrocolloid dressing and PRP covered with a gelatin sheet in the treatment of chronic skin ulcers. The efficacy of PRP for the treatment of chronic wounds in clinical trials is still controversial.\(^{10-12}\) Our gelatin hydrogel sheet has been applied in clinical trials mainly as a DDS for bFGF, and its efficacy and safety have been reported.\(^{17, 18}\) bFGF can be used clinically in Japan; however, the application of bFGF is not approved in other countries.\(^{7, 10, 20}\) The clinical usage of growth factors in these countries is limited. PRP can be prepared from the patient’s blood or donated platelets in all countries. Some bioengineered skin substitutes that provide growth factors secreted by living cells have been reported to be effective for chronic skin ulcers, although they are costly and access is also limited to only a few areas.\(^{21-23}\) Our gelatin sheet is freeze-dried and can be stored at room temperature for months. Therefore, it is possible to use this combination therapy consisting of PRP and a gelatin sheet anywhere when needed, and its efficacy might be superior to that of bioengineered skin substitutes, as these treatments have a similar mechanism of action in secreting growth factors in a sustained manner. Regarding the limitation of this study, this study included ulcers of various causes that could be potential for bias by different concomitant therapies. Therefore, we will plan the clinical study limited to one ulcer cause with standardised concomitant therapy in the next step. This is our first trial using the PRP/gelatin hydrogel sheet and we focused mainly on safety in this study, and evaluate the efficacy in the next step limited to one ulcer cause.

If successful, this intervention may lead to substantial and important changes in the management of increasingly prevalent chronic skin ulcers, such as diabetes ulcers and venous leg ulcers.

Contributors
NM, NK and KK initiated the study design. NM prepared the first draft of the manuscript. NM, NK, TO, TH, KS and KK will treat patients and conduct the clinical trial. NM will generate the allocation sequence, enrol participants and assign the participants to the interventions. MM, MY and YT provided contributions from the engineering aspect for the gelatin sheets, and prepared and supplied the sheets. MM is a grant holder. All authors contributed to refining the study protocol and approved the final manuscript.

Funding
This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI grant number 24390399 (https://kaken.nii.ac.jp/pd/p/24390399.en.html).

Competing interests
None declared.

Patient consent
Obtained.

Ethics approval
Institutional Review Board of Kansai Medical University.

Provenance and peer review
Not commissioned; externally peer reviewed.

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


Exploratory clinical trial of combination wound therapy with a gelatin sheet and platelet-rich plasma in patients with chronic skin ulcers: study protocol

Naoki Morimoto, Natsuko Kakudo, Makoto Matsui, Tsunetaka Ogura, Tomoya Hara, Kenji Suzuki, Masaya Yamamoto, Yasuhiko Tabata and Kenji Kusumoto

BMJ Open 2015 5:
doi: 10.1136/bmjopen-2015-007733

Updated information and services can be found at:
http://bmjopen.bmj.com/content/5/5/e007733

These include:

References
This article cites 23 articles, 0 of which you can access for free at:
http://bmjopen.bmj.com/content/5/5/e007733#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Dermatology (40)
- Surgery (278)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/